#WCLC2026
LightNews LightNews
lungcancereurope.bsky.social
Our President joined speakers from across the lung cancer community at #WCLC2026 today for From Evidence to Action: Practical Skills for Engaging Policymakers on Earlier #LungCancer Detection.

She spoke about handling objections to
screening & how advocates can respond when concerns are raised.
September 12, 2026 at 7:23 AM
jfreemandaily.bsky.social
#LivingWithLungCancer #WCLC2026
Patients and Caregivers at ROS1ders 2024 PRIME Summit
September 5, 2026 at 3:59 AM
cancertherapyadv.bsky.social
First-line trastuzumab deruxtecan (T-DXd) prolongs PFS, but not overall survival, in metastatic, HER2-mutant #NSCLC

Julia Rotow, MD, from @danafarber.bsky.social presented research from the DESTINY-Lung 04 trial this week at #WCLC2026 @iaslc.bsky.social

Full article: https://bit.ly/4gY7oK6
September 18, 2026 at 4:31 PM
shalinivinod.bsky.social
Ever wondered whether more intensive strategies increase uptake of lung cancer screening? Trial protocol here. Results @iaslc.bsky.social WCLC2026 link.springer.com/article/10.1...
Ready to screen implementation trial protocol: a cluster randomized implementation trial comparing a bundled implementation strategy versus a simple implementation strategy to improve intention to scr...
Background Uptake of lung cancer screening (LCS) in high-risk populations remains suboptimal internationally. Primary care practitioners play a critical role in identifying eligible patients and initi...
link.springer.com
May 13, 2026 at 7:16 PM
onc-rg.bsky.social
Join our team as we break down the major readouts from WCLC 2026 and discuss what key signals to watch for as we head into ESMO 2026!
Register: events.teams.microsoft.com/event/681070...

#WCLC2026 #ESMO2026 #LungCancer #Oncology
ONCrg Live Event: WCLC Insights into ESMO Signals 📅 Date: Wednesday, Oct 7th at 1pm ET Join our team as we break down the major readouts from WCLC 2026 and discuss what key signals to watch for as we head into ESMO 2026! 👇 What specific topics or questions are you hoping we cover during the live event? Let us know in the comments or when you register for the event! #WCLC2026 #ESMO2026 #LungCancer #Oncology #clinicalinsights #competitiveintelligence #nsclc #sclc #oncrg #bprg
September 18, 2026 at 1:34 PM
cancers-mdpi.bsky.social
📸 Great catching up with so many esteemed researchers and experts in the lung cancer community at #WCLC2026!

If you are at the conference, drop by booth #706 to connect with our team! ✨

#LungCancer #CancersMDPI #Oncology @iaslc.bsky.social
September 14, 2026 at 2:02 AM
new3rd.bsky.social
新たな希望！EGFR変異陽性肺がん治療に関する最新情報をWCLC2026で発表#肺がん#ライブリバント#EGFR遺伝子変異

国際肺癌学会WCLC2026で、ライブリバント治療がEGFR遺伝子変異陽性肺がん患者の生存期間を延長することが報告されました。
新たな希望！EGFR変異陽性肺がん治療に関する最新情報をWCLC2026で発表
国際肺癌学会WCLC2026で、ライブリバント治療がEGFR遺伝子変異陽性肺がん患者の生存期間を延長することが報告されました。
news.3rd-in.co.jp
September 18, 2026 at 8:14 AM
new3rd.bsky.social
リブロファズとラズクルーズ併用による肺がん治療の新たな展望#肺がん治療#ラズクルーズ#リブロファズ

リブロファズとラズクルーズの併用療法が、WCLC2026で低い治療関連事象発現率を報告。予防的支持療法の効果も注目されています。
リブロファズとラズクルーズ併用による肺がん治療の新たな展望
リブロファズとラズクルーズの併用療法が、WCLC2026で低い治療関連事象発現率を報告。予防的支持療法の効果も注目されています。
news.3rd-in.co.jp
September 18, 2026 at 8:14 AM
tokyo-days.bsky.social
リブロファズとラズクルーズの併用療法、WCLC2026で低い副作用率を報告#リブロファズ#ラズクルーズ#肺がん治療

リブロファズとラズクルーズの治療併用により、肺がん患者の副作用発現率が低下することが、日本で開催された肺癌学会で報告されました。
リブロファズとラズクルーズの併用療法、WCLC2026で低い副作用率を報告
リブロファズとラズクルーズの治療併用により、肺がん患者の副作用発現率が低下することが、日本で開催された肺癌学会で報告されました。
tokyo.publishing.3rd-in.co.jp
September 18, 2026 at 8:20 AM
tokyo-days.bsky.social
ライブリバント治療が肺がん生存率向上に貢献した最新研究の発表#ライブリバント#EGFR変異#リブロファズ

WCLC2026で発表された最新の研究により、EGFR陽性肺がん治療におけるライブリバントとリブロファズの有効性が確認され、患者の生存期間が延長される可能性が示されました。
ライブリバント治療が肺がん生存率向上に貢献した最新研究の発表
WCLC2026で発表された最新の研究により、EGFR陽性肺がん治療におけるライブリバントとリブロファズの有効性が確認され、患者の生存期間が延長される可能性が示されました。
tokyo.publishing.3rd-in.co.jp
September 18, 2026 at 8:20 AM
ipharmaservices.bsky.social
DESTINY-Lung04: #Enhertu batte chemio+pembro in 1L #NSCLC HER2+ • PFS: 14,3 vs 8,3m • ORR: 70% vs 44,5% • OS: 29,3 vs 33,1m

www.ipharmacenter.com/post/iaslc-2...

#WCLC26 #WCLC2026 #OncoAlert #OncoTwitter #notizie #media #TumoreAlPolmone
IASLC 2026 World Conference on Lung Cancer (#WCLC26) | 2026 | iPharmaCenter
Eight-Year ADAURA Update Shows Osimertinib Continuing to Extend Survival After Surgery in EGFR-Mutated Lung CancerAstraZeneca's osimertinib has maintained a substantial survival advantage nearly a dec...
www.ipharmacenter.com
September 17, 2026 at 3:44 PM
ipharmaservices.bsky.social
DESTINY-Lung04: #Enhertu supera quimio+pembro em 1L #CPNPC HER2+
• SLP: 14,3 vs 8,3m
• TRO: 70% vs 44,5%
• SG: 29,3 vs 33,1m

www.ipharmacenter.com/post/iaslc-2...

#WCLC26 #WCLC2026 #OncoAlert #OncoTwitter #notícias #mídia #CâncerDePulmão
IASLC 2026 World Conference on Lung Cancer (#WCLC26) | 2026 | iPharmaCenter
Eight-Year ADAURA Update Shows Osimertinib Continuing to Extend Survival After Surgery in EGFR-Mutated Lung CancerAstraZeneca's osimertinib has maintained a substantial survival advantage nearly a dec...
www.ipharmacenter.com
September 17, 2026 at 3:45 PM
ipharmaservices.bsky.social
DESTINY-Lung04 : #Enhertu bat chimio+pembro en 1L #CBNPC HER2+
• SSP : 14,3 vs 8,3m
• TRG : 70% vs 44,5%
• SG : 29,3 vs 33,1m

www.ipharmacenter.com/post/iaslc-2...

#WCLC26 #WCLC2026 #OncoAlert #OncoTwitter #news #media #CancerDuPoumon #HER2
IASLC 2026 World Conference on Lung Cancer (#WCLC26) | 2026 | iPharmaCenter
Eight-Year ADAURA Update Shows Osimertinib Continuing to Extend Survival After Surgery in EGFR-Mutated Lung CancerAstraZeneca's osimertinib has maintained a substantial survival advantage nearly a dec...
www.ipharmacenter.com
September 17, 2026 at 2:29 PM
ipharmaservices.bsky.social
DESTINY-Lung04: #Enhertu schlägt Chemo+Pembro in 1L HER2+ #NSCLC
• PFS: 14,3 vs 8,3M
• ORR: 70% vs 44,5%
• OS: 29,3 vs 33,1M

www.ipharmacenter.com/post/iaslc-2...

#WCLC26 #WCLC2026 #OncoAlert #OncoTwitter #Nachrichten #Medien #Lungenkrebs
IASLC 2026 World Conference on Lung Cancer (#WCLC26) | 2026 | iPharmaCenter
Eight-Year ADAURA Update Shows Osimertinib Continuing to Extend Survival After Surgery in EGFR-Mutated Lung CancerAstraZeneca's osimertinib has maintained a substantial survival advantage nearly a dec...
www.ipharmacenter.com
September 17, 2026 at 2:29 PM
ipharmaservices.bsky.social
DESTINY-Lung04: #Enhertu supera quimio+pembro en 1L #CPNM HER2+
• SLP: 14,3 vs 8,3m
• TRO: 70% vs 44,5%
• SG: 29,3 vs 33,1m

www.ipharmacenter.com/post/iaslc-2...

#WCLC26 #WCLC2026 #OncoAlert #OncoTwitter #news #media #CáncerDePulmón #HER2
IASLC 2026 World Conference on Lung Cancer (#WCLC26) | 2026 | iPharmaCenter
Eight-Year ADAURA Update Shows Osimertinib Continuing to Extend Survival After Surgery in EGFR-Mutated Lung CancerAstraZeneca's osimertinib has maintained a substantial survival advantage nearly a dec...
www.ipharmacenter.com
September 17, 2026 at 2:28 PM
ipharmaservices.bsky.social
DESTINY-Lung04：#Enhertu 在1L HER2突变 #非小细胞肺癌 击败化疗+帕博利珠单抗。
• PFS: 14.3 vs 8.3月
• ORR: 70% vs 44.5%
• OS: 29.3 vs 33.1月

www.ipharmacenter.com/post/iaslc-2...

#WCLC26 #WCLC2026 #OncoAlert #OncoTwitter #新闻 #媒体 #肺癌
IASLC 2026 World Conference on Lung Cancer (#WCLC26) | 2026 | iPharmaCenter
Eight-Year ADAURA Update Shows Osimertinib Continuing to Extend Survival After Surgery in EGFR-Mutated Lung CancerAstraZeneca's osimertinib has maintained a substantial survival advantage nearly a dec...
www.ipharmacenter.com
September 17, 2026 at 3:46 PM
firstwordgroup.com
Roche, MediLink's ADC boost survival in relapsed SCLC #$RHHBY #WCLC2026 firstwordpharma.com/story/7990444
September 15, 2026 at 4:36 AM
firstwordgroup.com
BioNTech, OncoC4 tout survival benefit for anti-CTLA-4 in NSCLC #$BNTX #WCLC2026 firstwordpharma.com/story/7987350
September 15, 2026 at 4:33 AM
trackerbiobank.bsky.social
🌏 That’s a wrap on #WCLC2026!

Congratulations to Dr Stephen Wong on a fantastic poster, highlighting methylation differences between immunotherapy responders and non-responders and potential biomarkers of treatment response and resistance in lung cancer. 👏

#LungCancer #Biobank
September 15, 2026 at 10:59 PM
firstwordgroup.com
Enhertu's PFS lung cancer win comes with an OS question mark #$AZN #$DSNKY #WCLC2026 firstwordpharma.com/story/7990485
September 15, 2026 at 4:32 AM
firstwordgroup.com
J&J's Rybrevant shows numerical OS gain in difficult-to-treat lung cancer #$JNJ #WCLC2026 firstwordpharma.com/story/7989702
September 15, 2026 at 4:34 AM
cancertherapyadv.bsky.social
Phase 3 REZILIENT3 trial results presented at #WCLC2026:

Adding the TKI zipalertinib to 1L chemotherapy improves outcomes in EGFR ex20ins #NSCLC:
• Median PFS: 14.5 vs 8.5 mos
• ORR: 65.0% vs 40.3%
• Median DOR: 14.2 vs 9.9 mos

Full Article: https://bit.ly/46pC3Kk
September 15, 2026 at 6:52 PM
cancers-mdpi.bsky.social
🤗We were delighted to meet with our editors in person at #WCLC2026!

Thank you for the insightful conversations and continued support in advancing high-quality research in lung cancer✨
#LungCancer #ThoracicOncology #CancersMDPI
September 15, 2026 at 7:43 AM
ipharmaservices.bsky.social
#Enhertu alcanzó 14,3 meses de mediana de SLP vs 8,3 meses con #pembrolizumab + quimio en 1L para #CPCNP con mutación HER2
www.ipharmacenter.com/post/iaslc-2...
#WCLC2026 #WCLC26 #Oncología
IASLC 2026 World Conference on Lung Cancer (#WCLC26) | 2026 | iPharmaCenter
Enhertu Becomes First HER2-Targeted Therapy to Beat Standard Care in Frontline Lung Cancer, Extending Time Without Progression by Six MonthsAstraZeneca and Daiichi Sankyo have announced positive resul...
www.ipharmacenter.com
September 15, 2026 at 6:10 PM
ipharmaservices.bsky.social
DESTINY-Lung04 (Ph3) : #Enhertu atteint 14,3 m de SSP vs 8,3 m sous #pembrolizumab + chimio en 1L dans le #CPNPC muté HER2 (-37% risque décès/progression)
www.ipharmacenter.com/post/iaslc-2...
#WCLC2026 #WCLC26 #Oncologie
IASLC 2026 World Conference on Lung Cancer (#WCLC26) | 2026 | iPharmaCenter
Enhertu Becomes First HER2-Targeted Therapy to Beat Standard Care in Frontline Lung Cancer, Extending Time Without Progression by Six MonthsAstraZeneca and Daiichi Sankyo have announced positive resul...
www.ipharmacenter.com
September 15, 2026 at 6:11 PM